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As one of the few human tissues to recover without scars, bone’s capacity to remodel 
itself and recover from injury is undoubtedly impressive. However, non-union fractures and 
critical sized defects, often the result of trauma, disease-related fractures, and tumor resection, 
have great difficulty healing without intervention.  Common treatments for these maladies 
include using bone autografts and allografts to fill the defect, though each of these treatments 
have their own potential complications and drawbacks. Tissue engineering strategies aim to 
recreate bone or bone’s natural healing processes on a lab-made scaffold along with cells and 
therapeutics for implantation. In addition, recreation of bone-like functions by improving in vitro 
models is crucial for drug testing and mechanistic studies. One class of materials used for both 
therapeutics and in vitro modeling are hydrogels, water-swollen polymeric networks that often 
exhibit great biocompatibility due to their similarity to native extracellular matrix. Hydrogels’ 
fragile mechanical properties relative to the remarkable strength of bone limit their application in 
heavy load-bearing regions of bone.  Including nanomaterials within the polymeric network can 
both increase the strength of the network and allow exploitation of their unique abilities to 
interact with encapsulated cells and therapeutics. Here, we hypothesize that the inclusion of 
nanodiamonds, octahedral carbon-based nanoparticles, can both improve the mechanical 
properties of a gelatin methacrylamide system and enable dexamethasone loading and delivery to 
encapsulated human adipose-derived mesenchymal stem cells. In the first section, we review 
bone tissue engineering strategies with a focus on hydrogels and carbon nanomaterials. In the 
second section, this project and its results are reported and analyzed, and finally, ideas for future 
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Introduction: A Review of Bone Tissue Engineering 
1.1 Abstract 
Bone’s natural healing capacity is seriously hampered and often nonexistent in the case 
of nonunion fractures and critical-sized defects. Often the result of serious trauma or tumor 
resection, both critical-sized defects and nonunion fractures are unable to heal without 
intervention. Autografts and allografts are the current major treatment options to aid in bone 
recovery, but both carry drawbacks and can result in serious complications. Bone tissue 
engineering strategies aim to eliminate these by using rationally designed scaffolds that enhance 
healthy bone regrowth into defects. Combining scaffolds with therapeutics, be they drugs, 
proteins, or cells, enriches the healing capacity of the scaffold and is the subject of intense 
research. One class of promising scaffolding material are hydrogels, composed of a hydrophilic 
polymeric network that closely resembles extracellular matrix, have high biocompatibility, 
tunable physical and mechanical properties, and the ability to encapsulate therapeutics and cells 
within the network. However, unmodified hydrogels frequently have low compressive elastic 
moduli as well as fracture strength that limit their efficacy in load-bearing defects. Including 
nanomaterials within hydrogels can enhance their mechanical properties due to interaction 
between material and polymer and can also modulate therapeutic loading and release. Carbon 
nanomaterials, such as graphene, carbon nanotubes, and nanodiamonds, have attracted broad 
attention in tissue engineering due to their unique properties. Integrating carbon nanomaterials 
and hydrogels allows researchers to take advantage of these properties. Here, we discuss bone 
physiology, general bone tissue engineering strategies, hydrogels for bone tissue engineering, 
and finally the potential use of carbon nanomaterials in bone tissue engineering. 
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1.2 Bone Physiology and Disease 
Healthy bone orchestrates an impressive variety of physiological tasks. Its most obvious 
role is protecting internal organs and providing support for movement thanks to its superb 
compressive and tensile strength, with a Young’s modulus ranging from 12-25 GPa [1] in 
cortical bone and 0.1-0.5 GPa [2] in cancellous bone. Bone and bone marrow also produce blood 
and aid in its pH regulation, act as a store for minerals, and host mesenchymal and hematopoietic 
stem cells. Composed of ~40% type I collagen fibers and ~50% hydroxyapatite crystals, bone’s 
anisotropic composite structure results in great compressive strength. Collagen fibers, parallel to 
the direction of compressive stress, are decorated in an ordered fashion with plate-like 
hydroxyapatite crystals with dimensions of around 2x30x40 nm [3, 4]. Both cortical and 
cancellous bone play vital roles in bone physiology. Cortical bone, which forms the outer shell of 
bones, is significantly denser than its counterpart and thus is crucial to load bearing and 
movement. Cancellous bone is located at the ends of long bones such as the femur and performs 
bone’s other functions. These other tasks are just as crucial as load bearing; cancellous bone is 
highly vascularized to support calcium exchange with the blood and is awash with red bone 
marrow containing hematopoietic and mesenchymal stem cells. At the cellular level, osteoblasts, 
osteoclasts, and osteocytes contribute to bone homeostasis by overseeing a fine balance of type I 
collagen and hydroxyapatite deposition and remodeling. A disruption of this balance by a wide 
variety of factors can lead to diseases such as osteoporosis and osteoarthritis. 
When bone is damaged by a fracture or medical procedure, it is normally able to heal 
itself effectively by intramembranous and endochondral ossification. Initially, a hematoma forms 
around the fracture and infiltrating macrophages and osteoclasts remove damaged pieces of bone 
and other tissue. In intramembranous ossification, the periosteum, the fibrous, outermost layer of 
bone, releases progenitor cells to form a bony callous around the periphery of each side of the 
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fracture, while the process of endochondral ossification bridges the gap between fracture ends by 
forming a fibrous cartilaginous matrix. After these processes are complete, blood vessels 
infiltrate the callus and the cartilaginous matrix is resorbed as new bone is deposited in its place 
to form a hard callus throughout the fracture and around its periphery. Finally, normal 
homeostatic osteoblast and osteoclast turnover resorbs excess bone from the callus and deposits 
new matrix in its place; this property of bone is unique among human tissue, as no scar formation 
occurs after fracture [5, 6]. 
Though bone has an impressive capacity to heal naturally, an array of diseases present 
physicians and surgeons with numerous hurdles for effective treatment. Major degenerative 
diseases such as osteoporosis and osteoarthritis and their increased risk of serious fractures [7, 8] 
plague our quickly growing elderly population; total joint replacements have increased 
dramatically over the last 15 years [9, 10]. Demand continues to grow, with total amounts of 
both knee and hip arthroplasty procedures growing by ~6% from 2009-10 [11]. Less prevalent 
diseases such as congenital osteogenesis imperfecta and temporary or chronic bacterial infections 
in osteomyelitis also present a serious burden on patients. Orthopedic surgeons are faced with the 
effects of not just osteoarthritis, osteoporosis, and other common bone diseases, but must address 
difficult-to-treat traumatic bone fractures. In addition, resection of primary and secondary bone 
tumors by surgeons often requires removal of significant portions of bone tissue [12]. 
In many cases after surgery, bone is unable to heal normally. Difficulty healing due to 
infection or poor blood supply after a total joint replacement can result in a nonunion fracture, in 
which a fracture does not rejoin despite mechanical fixation. Nonunion fractures typically 
require surgical intervention for treatment [13]. Critical-sized defects are commonly caused by  
trauma and resection of tumors; this term is used to describe a void of tissue that will not heal 
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without treatment [14]. The current standard treatments for critical sized defect, bone autografts 
and allografts, have numerous drawbacks. In the case of autografts, tissue must first be removed 
from a secondary site, usually the pelvis, and used to fill the defect. Complications from 
autografts can include morbidity, pain, and infection at both the secondary site and the defect 
site; in addition, a lack of available healthy donor tissue can restrict the supply of autograft [15, 
16]. Allografts eliminate the need for a donor site and have reduced issues with supply, but carry 
their own drawbacks as well: donor tissue can risk disease transmission [17], infect the patient 
[18], or induce a patient inflammatory response to the implanted tissue. In addition, allografts 
typically do not integrate with host tissue as successfully as autografts do [19]. Greater than 2 
million bone grafts are performed every year worldwide [20], each with these potential risks. For 
these reasons, tissue engineering researchers have sought to create significantly better 
alternatives to grafting for the repair of critical-sized defects and to aid in the healing process for 
non-union fractures. In addition to their goals to eventually replace tissue and current grafting 
technology, tissue engineers also aim to develop better in vitro models of bone and bone diseases 
for mechanistic studies and drug discovery and testing. In the following sections, we overview 
current strategies in this field, with a focus on biopolymers, and finally hydrogels and 
nanocomposite hydrogels for therapeutic use and modeling. 
1.3 Bone Tissue Engineering Strategies 
Using biomimetic synthetic scaffolds, to replace critical-sized defects and aid in the 
repair of non-unions has the potential to solve the issues presented by autograft and allograft use. 
Using synthetic or abundant biologically-derived materials like gelatin, of which researchers 
possess unlimited amounts compared to typical grafting materials, eliminates the issues to which 
both autografts and allografts are prone. In their review of biomimetic bone tissue engineering, 
5 
 
Porter et al. listed a daunting eleven requirements for a perfect tissue engineered bone 
replacement [21]. To summarize, it must provide mechanical support while the tissue heals and 
encourage self-integration with surrounding tissue, be porous enough for vascularization and 
cellular infiltration, promote osteogenic differentiation of infiltrating mesenchymal stem cells, 
have a controlled degradation profile without releasing toxic or inflammatory products, and 
finally deliver therapeutics or cells in a controlled, effective fashion. Several major scaffold 
types, porous and fibrous scaffolds along with hydrogels, composed of wide-ranging synthetic 
polymers [22] and biopolymers [23] have been the focus of research in this field. Polymers are 
frequently combined with ceramics, bioactive glasses, and nanomaterials in attempts to recreate 
the composite structure of bone [24, 25]. Combining these scaffolds with cells, therapeutics, or 
both can enhance their regenerative capabilities significantly [21]. Mesenchymal stem cells 
(MSCs) normally migrate to damaged bone, and when included in a scaffold can both modulate 
the host response to an implant in vivo and differentiate along chondrogenic or osteogenic 
lineages to speed healing [26, 27]. Drugs such as the osteoinductive dexamethasone [28], 
proteins of the bone morphogenetic protein family and vascularization enhancers like platelet-
derived growth factor [29], and nucleic acids as plasmids or siRNA [30, 31] are a few examples 
of therapeutics used in concert with scaffolds and cells. The available strategies for bone tissue 
engineering are presented in Figure 1.1. In the following sections, we offer a brief review and 
several examples of the major components of the project presented in Chapter 2. A variety of 
biopolymers, including the gelatin used in this project, for bone tissue engineering are presented 
in the next section. Next, we present several examples and the advantages and disadvantages of 
using biopolymer hydrogels in bone tissue engineering. Finally, a brief overview of filling agents 
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leads us into a discussion of carbon nanomaterials, in particular nanodiamonds, and the 
presentation of our work in the following chapter. 
1.3.1 Biopolymers for Bone Tissue Engineering 
Biopolymers, including structural proteins, glycosaminoglycans (GAGs), or 
polysaccharides, frequently exhibit superior biocompatibility to synthetic polymers. Infiltration, 
adhesion, and migration of cells within biopolymer scaffolds is significantly easier. However, 
concerns remain about their reduced versatility compared to synthetic polymers, batch to batch 
variability, and potential immunogenicity of non-human biopolymers remain. Though 
biopolymers inherently have less versatility than synthetic ones, creative chemical modifications 
and scaffold fabrication strategies by researchers have resulted in impressive flexibility. For 
example, solvent casting, particulate leaching, and 3D printing have been used to create and 
modify porous scaffolds and hydrogels [32], while electrospinning can create a wide variety of 
polymeric nanofibers [33]. Several of the most attractive and widely used biopolymers are 
alginate, chitosan, hyaluronic acid, and collagen/gelatin. Alginate, an anionic polysaccharide 
derived from brown algae, displays excellent biocompatibility and quick and simple gelation. 
Alginate microspheres crosslinked with calcium chloride have shown encouraging applications: 
Zhao et al. combined calcium phosphate paste with alginate-based microspheres encapsulating 
umbilical cord mesenchymal stem cells (hUCMSCs); this system showed both mechanical 
properties on the order of cancellous bone and effective differentiation of the hUCMSCs into 
osteoblasts [34]. Chitin is a structural, cationic polysaccharide that can be extracted from insects 
and crustaceans, then hydrolyzed to chtosan. Collagen/chitosan thermogels have been created by 
using β-glycerophosphate, normally used as an osteogenic supplement, as an ionic crosslinking 
agent [35]. As a GAG, hyaluronic acid is usually used in cartilage tissue engineering [36]; 
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studies attempting osteochondral interface development frequently utilize it. Patterson et al. 
studied glicidyl-methacrylate modified hyaluronic acid hydrogels codelivering BMP-2 and 
vascular endothelial growth factor (VEGF) with different degradation rates, finding that the most 
quickly and most slowly degrading hydrogels showed increased new bone formation [37]. 
Collagen and gelatin, as derivatives of the major structural protein of bone, are perhaps the most 
attractive options for future clinical translation. Collagen is composed of three α-helices of the 
form Gly-X-Y with very frequent proline and hydroxyproline residues. These helices themselves 
self-assemble into triple helices, which further assemble into collagen fibrils that are 
enzymatically crosslinked in vivo. Gelatin is simply denatured collagen, whereby heat and an 
acid or base treatment has been used to hydrolyze crosslinks, resulting in a randomly coiled 
structure. Both polymers, as one might expect, show high biocompatibility with many cell lines, 
given the multitude of cellular adhesion sites for cell traction and migration. In the 
chitosan/collagen composite study previously mentioned, the inclusion of collagen allowed for 
significantly enhanced cell proliferation. Cellular DNA content in pure chitosan scaffolds halved 
over the course of two weeks, while the addition of collagen helped double the amount of DNA 
in the scaffold over the same time [35]. Combining collagen/gelatin and various hydroxyapatite 
materials has been a successful strategy. Perez et al. crafted gelatin/hydroxyapatite microspheres 
using a water-in-oil immersion method [38] that could be used for controlled delivery of 
osteogenic factors. Gelatin inclusion enabled excellent cellular adhesion and proliferation 
compared to hydroxyapatite spheres alone. Though recombinant BMP-2 (rBMP-2) is an FDA-
approved treatment in spinal fusion products, its uncontrolled release into surrounding tissues 
has led to serious side effects. Collagen, nanohydroxyapatite (nHA), and alginate microspheres 
containing rBMP-2 were used to create a porous scaffold interspersed with microspheres. 
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Alginate microspheres resulted in significantly greater extension and control over growth factor 
release [39]. Biopolymers can be used to create a variety of scaffold types, including remarkably 
versatile hydrogels. In the next section, we overview hydrogels and their applications and limits 
in bone tissue engineering. 
1.3.2 Hydrogels for Bone Tissue Engineering  
Hydrogels are composed of a water-swollen network of typically randomly arranged 
hydrophilic polymer chains that more closely recapitulates native ECM than the fibrous or 
porous scaffolds mentioned above. From both synthetic polymers and biopolymers, tissue 
engineers have created hydrogels with tunable mechanical properties [40], porosities [32], and 
degradation profiles [37, 41] to mimic targeted tissues and control therapeutic delivery. In 
addition, numerous physical and chemical crosslinking methods allow control over gelation 
conditions. In particular, photocrosslinkable and thermogelling hydrogels are promising for 
eventual application in regenerative medicine; the ease of cell encapsulation along with the 
injectability of their prepolymer solution easily delivers cells to the target site and allows for 
filling of iregullar defects [35, 42]. Hydrogels are also a valuable tool for creating more 
sophisticated 3D cell culture techniques in efforts to enhance the accuracy and thus add 
applicability to in vitro studies [43, 44]. With applications such as the generation of 
microvascular networks [45], microgel fabrication to study differentiation processes [46], and 
regenerative medicine approaches for numerous tissues [42], gelatin methacrylamide (GelMA), 
used in this study, is one example of a photocrosslinkable polymer with applications in both 
therapeutics and novel in vitro constructs. 
Unfortunately, hydrogels generally lack both the compressive strength and fracture 
properties of more robust fibrous and porous scaffolds, and this can limit their application in 
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heavy load-bearing defects. As a result, hydrogels have been explored as an option for filling in 
craniofacial defects from trauma or tumor resection, in which their reduced mechanical 
properties are not a significant liability [47, 48]. In addition, several recent studies suggest that 
exploiting the natural healing process by implanting a scaffold that stimulates endochondral 
ossification and encourages vascularization may be a more effective strategy for treatment than 
implanting simply bone-like scaffolds [49-52]. Hydrogels, with their controllable porosity and 
degradation profiles, have the properties needed to facilitate vascularization and emulate 
endochondral ossification. Hyaluronic acid hydrogels and GelMA hydrogels containing MSCs 
primed for chondrogenesis by inclusion of decellularized cartilage particles have been used for 
this purpose [50, 51]. One particularly interesting approach was a spheroid coculture of human 
umbilical vein endothelial cells (HUVECs) and MSCs stimulated by Sonic Hedgehog (Shh) 
combined within a calcium phosphate and collagen hydrogel. Shh is a crucial morphogen during 
embryonic development, but also vital for neovascularization [53]. Rivron et al. hypothesized 
that enhanced vascularization would direct a defect to begin endochondral ossification and then 
mature into bone, and proved this in vivo [54]. 
Despite their emerging potential with regards to endochondral ossification, it is still vital 
to improve hydrogel mechanical properties to realize further application to bone and other 
tissues. For this reason, exploiting filling agents, especially nanomaterials, is an attractive option 
for enhancing their mechanical properties while taking advantage of the diverse chemical and 
biological capabilities nanomaterials can offer. As they are with other scaffold types, 
hydroxyapatite and clay materials are excellent filling agents for hydrogel-based bone 
applications. PEG diacrylate (PEGDA) and GelMA have both been used in combination with 
discoidal silicate nanoparticles (Laponite). The Laponite both enhanced the mechanical 
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properties of the GelMA and PEGDA and promoted osteogenic differentiation of encapsulated 
preosteoblasts in the GelMA system [55, 56]. Fu et al. combined collagen and nHA with an 
injectable, thermogelling copolymer (PEG-PCL-PEG), and implantation in rabbits showed 
favorable, nearly complete regeneration of a critical-sized defect [57]. These materials are 
excellent for strategies to emulate the biphasic organic/inorganic nature of bone, but other tools 
such as carbon nanomaterials offer very unique properties and functionalization strategies for 
therapeutic delivery and can enhance the mechanical properties of scaffolds. 
1.3.3 Carbon Nanomaterials for Bone Tissue Engineering 
Carbon nanomaterials, including graphene and graphene oxide (GO), single- and multi-
walled carbon nanotubes (CNTs), and nanodiamonds (NDs), are another class of nanomaterials 
which have been explored for bone tissue engineering and drug delivery purposes. These 
materials offer several advantages over the typically used calcium phosphate minerals, 
biogalsses, and nanoscale clay. Firstly, the unique mechanical, electrical, and optical properties 
of the carbon nanomaterials offer unique opportunities across all tissue engineering disciplines. 
In addition, they have much more versatile functionalization strategies and therefore the potential 
to deliver many therapeutic classes in a variety of ways. Graphene has been shown to aid in 
neuronal, cardiomyogenic, and osteogenic differentiation of related progenitor cells [58-60]. GO, 
when grafted onto titanium implants, was able to adsorb significant amounts of BMP-2 and 
differentiate MSCs resulting in enhanced bone repair in vivo [61].  Multi-walled CNTs have also 
been shown to induce osteogenic differentiation of mesenchymal stem cells [62]. Carboxylated 
MWCNTs modified the physical properties of chitosan/hydroxyapatite scaffolds by electrostatic 
interactions with chitosan, increasing the thermal stability, porosity, and improving the growth 
rates of cultured osteoblasts [63]. 
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Though CNTs and graphene have been used in bone tissue engineering, exploration of 
NDs for use in tissue engineering scaffolds has been limited. NDs are carbon nanoparticles, 
typically around ~5 nm but with some larger varieties, with a core of diamond lattice and a 
variety of surface moieties [64]. Traditionally derived from detonation of explosive mixtures 
with a negative oxygen balance, NDs have been synthesized in a variety of ways in recent years 
[64]. Perhaps the most attractive aspect of NDs is their versatile surface chemistry. Carboxylated, 
hydroxylated, hydrogenated, and amine-functionalized NDs are just a few of the many possible 
surface modifications [65]. In addition, NDs are significantly less toxic than other carbon 
nanomaterials [66]. To date, biomedical research using NDs has focused mostly on systemic 
administration of NDs with surface-functionalized drugs as well as fluorescent NDs for 
applications in cancer therapy and diagnostics. ND/doxorubicin complexes reduced tumor size in 
a mouse model more effectively than doxorubicin alone, likely due to tropism towards tumors by 
the enhanced permeability and retention effect and avoidance of drug efflux pumps once inside 
the cell [67]. NDs with highly carboxylated surfaces have been used to deliver plasmid DNA 
[31] and siRNA [68]. Initial complexation with positively charged polyethyleneimine (PEI) 
allows the NDs to then associate with negatively charged nucleic acid chains. Several groups 
have also reported protein complexation with NDs. Figure 1.2 visualizes these different drug 
delivery strategies. Moore et al. complexed both basic fibroblast growth factor (bFGF) and 
BMP2 to NDs simultaneously; the complex initiated osteogenic differentiation and accelerated 
proliferation of mouse myoblasts [69]. In a nanocomposite application, octadecylamine was 
covalently linked with NDs for imaging purposes, then mixed within a poly(lactic acid) (PLA) 
matrix, increasing the mechanical properties of the scaffold to that of cancellous bone [70]. 
Limited research has been performed on ND interactions with stem cells as well as their 
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capabilities in tissue engineering, in particular with their influence on hydrogel properties. 
However, the unique properties of NDs, including their highly modifiable surfaces and high 
surface area, the possibility to covalently link or adsorb therapeutics to their surface, and perhaps 
most significantly, their much higher biocompatibility compared to other carbon nanomaterials, 
should encourage further study in tissue engineering applications. 
1.4 Conclusion 
Despite relatively fragile mechanical properties, biocompatible and tunable biopolymer 
hydrogels are an active topic of research for bone tissue engineering. Filling agents, especially on 
the nanoscale, can add significant functionality and often increase the mechanical properties of 
hydrogels. The excellent biocompatibility of NDs, their hypothesized ability to enhance 
mechanical properties as a filling agent given the success of other carbon nanomaterials, and the 
ability to adsorb drugs on their surface makes them an excellent option for study in bone tissue 
engineering. The limited literature on NDs’ interactions with stem cells and their capabilities as a 
filling agent in hydrogels suggests further research needs to be done to demonstrate and evaluate 
their potential. This project was envisioned as an exploration of that potential, while holding 
several possible future applications in mind. As an initial proof of concept, we aimed to explore 
the effect of NDs as a filling agent and therapeutic deliverer. We chose both a widely used, well- 
characterized hydrogel (GelMA) as well as a model osteoinductive drug (dexamethasone) to 
elucidate the effectiveness of NDs to simultaneously modify GelMA physical and mechanical 
properties while also delivering a drug. In the following chapter, we present the capabilities of 
NDs to adsorb dexamethasone, modulate GelMA mechanical properties, and finally, induce 
osteogenic differentiation via dexamethasone release to encapsulated adipose-derived 




Gelatin-Nanodiamond Hydrogel for Drug Delivery and Bone Tissue Engineering 
2.1 Abstract 
Nanodiamonds (NDs), carbon-based nanoparticles typically between 4-5 nm, have 
attracted interest for biomedical applications due to their high surface area for adsorption and 
delivery of therapeutics, their modifiable surfaces, and their low toxicity. Research into the 
medical applications of NDs has largely focused on systemic administration of NDs, particularly 
for targeting tumors; thus, their integration into tissue engineering scaffolds and interactions with 
stem cells remains largely unexplored. Here, we report the synthesis of a nanocomposite 
hydrogel composed of NDs and gelatin methacrylamide (GelMA) to explore the physical and 
mechanical effects of NDs as a filling agent in addition to their well-known drug loading 
capabilities. Combining these two materials creates a flexible tissue engineering platform 
enabling the investigation of ND-drug complexes in 3D culture. To demonstrate these 
capabilities, we assess the potential of NDs to load dexamethasone within the GelMA network 
for the purposes of osteogenic differentiation of human adipose-derived stem cells (hASCs). We 
found that dexamethasone was readily loaded onto the NDs, and verified that this complex was 
capable of releasing the drug to hASCs in vitro. Inclusion of NDs within GelMA hydrogels 
nearly doubled the compressive strength of the hydrogels in the 2 mg/mL group, while the 
physical properties of the hydrogels were minimally changed. Integrating the ND-
Dexamethasone complex within GelMA hydrogels resulted in successful osteogenic 
differentiation of encapsulated hASCs, as measured by alkaline phosphatase activity, calcium 





Nanocomposite hydrogels have recently become an attractive subject of study for tissue 
engineering applications. Hydrogels themselves, in particular those composed of biopolymers 
like collagen, hyaluronic acid, and alginate, exhibit properties similar to native extracellular 
matrix (ECM) and as a result display stellar biocompatibility along with excellent cellular 
adhesion and mobility [71, 72]. As a result, cells encapsulated within hydrogels show high 
viability and hydrogel properties can even dictate stem cell behavior and differentiation [73]. 
One such naturally derived hydrogel system is gelatin methacrylamide (GelMA) which has 
shown excellent cellular motility, adhesion, and proliferation in many previous studies and 
allows for the formation of complex micropatterned and 3D-printed structures as a 
photocrosslinkable polymer [42, 74].  
In addition, GelMA has been used as a starting system for the synthesis of nanocomposite 
hydrogels. By using nanomaterials as filling agents to generate nanocomposites, researchers are 
able to create new properties for their scaffolds. Commonly, nanomaterials can modulate gel 
physical properties, enhance their mechanical properties, and allow more opportunities for 
cellular adhesion and proliferation with their high surface area:volume ratio [75]. In addition, 
certain nanomaterials are capable of loading therapeutics through covalent linking, electrostatic 
interactions, or physisorption [76]. 
Carbon nanomaterials, in particular graphene, single- and multi-walled carbon nanotubes 
(CNTs), and nanodiamonds (NDs) have garnered significant attention by biomedical researchers 
due to their unique mechanical, electrical, and optical properties. Both multi-walled CNTs and 
graphene have been shown to influence stem cell fate when integrated into tissue engineering 
scaffolds [77, 78], while NDs have been more limited in this area. All three of these materials 
have also been extensively explored for modifying intravenous drug delivery systems, given 
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their high surface area and functionality [76, 79]. In particular, NDs now boast a huge variety of 
surface functionalizations and synthesis techniques to create iterations such as carboxylated NDs, 
amine-functionalized NDs, and fluorescent NDs, among many others [64]. This tailoring has 
allowed researchers to demonstrate drug delivery of a variety of therapeutics, including small 
molecules [67, 80], proteins [69, 81], and nucleic acids [68, 82]. 
NDs have also been shown to be an effective filling agent in several studies. One report 
of their integration into a poly(L-lactic acid) non-hydrated porous scaffold improved the 
compressive strength of the scaffold to near that of cancellous bone [70]. Despite their efficacy 
as drug delivery vehicles, NDs remain underexplored for tissue engineering applications, 
especially with regards to nanocomposite hydrogels. Their demonstrated drug delivery 
capabilities, coupled with their significantly higher biocompatibility compared to the other 
carbon nanomaterials, necessitates further study in this field. We hypothesized that NDs could 
both effectively load and deliver a small molecule drug, dexamethasone (Dex), and add 
compressive strength to a conventional hydrogel, GelMA, for potential application as a bone 
tissue engineering scaffold. Dex is a glucocorticoid that is used clinically as an anti-
inflammatory medication, but is also regularly utilized to induce osteogenic differentiation of 
mesenchymal stem cells (MSCs) by mediating an  increase in the number of focal adhesions and 
intracellular tension, which in turn increases RUNX2 expression along with related osteogenic 
genes [83].  
The goal of this study was to investigate the potential of NDs as nanofillers for 
influencing the properties of GelMA hydrogels and as drug-loading agents within GelMA 
hydrogels for 3D bone tissue engineering. We investigate the biocompatibility of NDs and their 
ability to load dexamethasone (Dex) and interact with human adipose-derived mesenchymal 
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stem cells (hASCs), as well as the mechanical and physical effects of NDs on GelMA networks. 
Finally, we present successful 3D osteogenic differentiation of hASCs encapsulated within 
GelMA/ND-Dex nanocomposite hydrogels. 
2.3 Materials and Methods 
2.3.1 ND Characterization and Dexamethasone Loading 
To verify and quantify Dex (Sigma-Aldrich, USA) loading on the NDs (NanoAmor, 
USA), a dispersed ND suspension (2 mg/mL) was prepared in ethanol by sonication for 30 
minutes and subsequently mixed with in equal volume with a solution of dexamethasone-
fluorescein isothiocyanate (Dex-FITC) in ethanol (0.2 mg/mL) (Invitrogen, USA). Ethanol was 
chosen as a solvent to ensure full solubility of Dex-FITC throughout the study. 
A final suspension containing 1 mg/mL of ND and 0.1 mg/mL Dex-FITC was vortexed 
for five minutes to ensure thorough mixing of the suspension components. Visible spectra in the 
range of 400-600 nm was recorded for the complex prior to centrifugation. In addition, a solution 
of 0.1 mg/mL Dex-FITC and a suspension of 1 mg/mL NDs were prepared as controls and their 
UV-Vis spectra were recorded as well. All the samples were then centrifuged for 20 minutes at 
14,000 rpm. The supernatants were collected and their UV-Vis spectra recorded in the same 
range as stated above. Loading percentage was evaluated comparing the absorbance of Dex-
FITC prior and after centrifugation of the complex at 590 nm using the following equation: 100 - 
(Cpost / Cpre) * 100. 
2.3.2 hASC Cell Culture and ND-Dex Interactions with hASC 
Human adipose-derived stem cells (hASCs) were purchased from RoosterBio (USA) and 
maintained in α-MEM (Invitrogen, USA) with 15% FBS (v/v) and 1% penicillin/streptomycin 
(v/v) at 37 °C and 5% CO2. For differentiation studies, all cells used were in passage 3-5. 
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Several concentrations of NDs (10, 25, 50, 100, and 200 µg/mL) were added to hASCs in 
2D culture, after which a 12 hour MTT Assay was performed according to the manufacturer’s 
protocol (ATCC, USA) along with Calcein-AM staining (Invitrogen, USA). For apoptosis gene 
expression, hASCs were cultured in a 24-well plate with 500 μL complete media containing 50 
μL of either UP water as a negative control, 25 µg/mL NDs in UP water, or 50 µM camptothecin 
(Sigma-Aldrich, USA) as a positive control. After incubation for 12 hours, gene expression was 
analyzed using the RT-qPCR procedure detailed below. 
For observing ND-Dex interactions with hASCs, ND-Dex suspensions were prepared in 
ethanol, centrifuged for 20 minutes at 14,000 rpm, then resuspended in UP water and deposited 
onto hASCs in 500 μL complete media to a final concentration of 25 µg/mL ND and 1 µM Dex. 
Control groups were formulated in the same fashion using either UP water alone, 25 μg/mL NDs, 
or 1 uM Dex. Gene expression for Dex-related markers was then evaluated at 1 and 6 hours Dex 
exposure using the RT-qPCR procedure detailed below. 
Both apoptosis and dexamethasone exposure qPCR studies, mRNA from each group 
were first extracted using an RNeasy Mini Kit (Qiagen, Germany). mRNA concentrations were 
measured using a NanoDrop (Thermo Scientific, USA), then normalized (100 ng mRNA) for 
conversion to cDNA. mRNA solutions were converted to cDNA using the High-Capacity cDNA 
Conversion Kit (Applied Biosystems, USA). For qPCR, all primers used were predesigned 
KiCqStart SYBR Green primers (Sigma-Aldrich, USA). KiCqStart SYBR Green Master Mix 
was used for each reaction (Sigma-Aldrich, USA). All qPCR reactions were performed using a 
Mastercycler Realplex4 (Eppendorf, Germany). Fold expression levels were calculated using the 




hASCs were seeded onto chamber slides, allowed to adhere and grow in complete media, 
then serum starved for 48 hours. ND-Dex, NDs, Dex, and UP Water were added to hASCs in the 
same fashion as described in section 2.3.2 and allowed to incubate for 24 hours.  Cells were then 
fixed in 4% paraformaldehyde for 5 minutes at 37 °C, permeabilized with 0.3% Triton-X100 for 
10 minutes at room temperature, then blocked with 5% normal goat serum for 45 minutes at 
room temperature. Mouse anti-human paxillin antibody (1:400 with 1% goat serum, Invitrogen, 
USA) was added to cells and left overnight at 4 °C. Goat anti-mouse AlexaFluor 594 (1:500, 1% 
goat serum) was then added and left for one hour at room temperature. Diamidino-2-
phenylindole dilactate (DAPI, Invitrogen, USA) and phalloidin-AlexaFluor488 (Invitrogen, 
USA) were used to counterstain nuclei and F-actin, respectively. For staining of osteocalcin in 
the differentiation study, nanocomposites containing hASCs in osteoconductive media after 21 
days were fixed, permeabilized, and blocked as above, then stained with mouse anti-human 
osteocalcin antibody (1:100 with 1% goat serum) and goat anti-mouse AlexaFluor 594 (1:500, 
1% goat serum). 
2.3.4 Synthesis of Gelatin Methacrylamide and GelMA/ND Nanocomposites 
Gelatin A (300 g bloom from porcine skin) and methacrylic anhydride were purchased 
from Sigma-Aldrich (USA). GelMA was synthesized as previously described [84]. Briefly, a 
10% gelatin (w/v) solution prepared in PBS at pH 7.4 was heated to 60 °C. 8 mL of methacrylic 
anhydride was added dropwise to methacrylate amine groups along the gelatin backbones. The 
polymeric mixture was stirred vigorously and maintained at 60 °C for two hours to complete the 
reaction, then terminated by addition of 100 mL PBS. The prepared solution was then transferred 
to dialysis membranes (~12-14 kDa cutoff) and dialyzed with UP water for one week with two 
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daily water changes. The GelMA solution was then frozen at -80 °C and lyophilized for 72 
hours. 
To prepare the nanocomposite hydrogels, ND suspensions of 4 mg/mL were prepared by 
sonication in UP water for 30 minutes. After appropriate dilutions, ND suspensions were mixed 
with a 14% GelMA and 0.5% photoinitiator (PI) (Irgacure 2959, Sigma-Aldrich) prepolymer 
solution prepared in UP water to prepare final prepolymer solutions of 7% GelMA, 0.25% PI, 
and ND (0, 0.5, 1, and 2 mg/mL). Prepolymer solutions were then UV crosslinked (320-500 nm) 
(Omnicure S200, Lumen Dynamics, Canada) for six minutes at an intensity of 7 mW/cm2. 
2.3.5 Physical and Mechanical Characterization of GelMA/ND Nanocomposites 
In order to determine the swelling ratio, gels (n=5) for each group (0, 0.5, 1, and 2 
mg/mL ND) were created, then frozen at -80 °C then lyophilized for 24 hours. Gels were swollen 
in PBS at 37 °C. After dabbing on a KimWipe to remove excess water, gel weight was measured 
and compared to the dry weight [(Wet weight – dry weight)/dry weight) x 100] after 1, 4, 8, 24, 
48, and 72 hours.  
For all mechanical studies, nanocomposites were first swollen in PBS for 24 hours. 
Mechanical analysis of the nanocomposites was performed using an RSA-III dynamic mechanic 
analyzer (TA Instruments, USA) and an AR 2000 rheometer (TA Instruments, USA). 
Nanocomposite cylinders (n=5) with radius 4 mm and height 2 mm were uniaxially compressed 
at a rate of 0.05 mm/s to obtain stress vs. strain plots from which the compressive elastic moduli 
were calculated using the linear portion of the curve (1-10% strain). For rheological analysis, 
cylindrical gels with 15 mm diameter and 4 mm height were used. Frequency sweeps were 
carried out from 0.01 to 10 Hz at 10% strain (in the viscoelastic region) and strain sweeps were 
performed from 1% to 100% strain at 1 Hz. All rheological analyses were carried out at 37 °C. 
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2.3.6 Micropatterning of GelMA/ND Nanocomposites 
GelMA micropatterns were created using previously established procedures [74, 85]. 
Prior to cell encapsulation, glass slides were treated with 3-tri(methoxysilyl)propyl methacrylate 
(TMSPMA) (Sigma, USA). TMSPMA-coated slides were then coated with a 50 µm layer of 
polyethylene glycol diacrylate (PEGDA, Mw 1000 Da) (Sigma-Aldrich, USA) by UV 
crosslinking for 60 s. To prepare cell-laden micropatterns, hASCs were mixed with a 7% (w/v) 
GelMA pre-polymer solution containing 1 mg/mL of ND and 0.5% of PI. Cells were mixed in a 
cell density of 1.0 x 106 cells/mL of GelMA solution. A 45 µl of pre-polymer solution was then 
dropped on a petri-dish in between two spacers with a desirable height of 100 µm.  
Subsequently, the PEGDA coated glass slides were placed on top of the pre-polymeric 
solution to obtain the aforementioned thickness. Finally, a 1x1 cm photomask was positioned on 
the glass slide and the entire construct was exposed to UV light (7 mW/cm2 intensity) for 45 s. 
The PEGDA-coated glass slides containing patterned, crosslinked hydrogel constructs were 
submerged into warm DPBS. Following encapsulation, constructs were cultured in 6-well cell 
culture plates and supplemented with complete media. hASCs were stained using calcein-AM at 
5 and 10 days according to the manufacturer’s protocol (Invitrogen) and images were taken using 
a fluorescence microscope (Zeiss). 
2.3.7 Dex-FITC Release Study 
Lyophilized GelMA was mixed in PBS with 0.1% (w/v) PI to obtain a final GelMA 
concentration of 7% (w/v). Dex-FITC was mixed in the GelMA mixture at the concentration of 
250 μg/mL. Nanocomposite hydrogels (1 mg/mL) were similarly fabricated containing the same 
amount of Dex-FITC. The amount of Dex-FITC released over time was determined by 
measuring the amount of drug not bound and washed away from the hydrogels. Briefly, 40 μL of 
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each GelMA/Dex-FITC mixture was placed in 96-well plates and crosslinked at 7 mW/cm2 for 
60 s. All wells were then filled with 200 μL of PBS and replaced with fresh PBS every hour for 
the first 8 hours and subsequently every 24 hours until a plateau was reached. The 96-well plates 
were protected from light and the PBS incubation solution was transferred to a new well plate. 
The fluorescence intensity was measured at 493 nm excitation and 519 nm emission wavelengths 
in a Cytation 5 plate reader (BioTek, USA). The amount of Dex-FITC was quantified using a 
standard calibration curve in the range of 0.4 μg/mL to 18 μg/mL. The percent of Dex-FITC 
release was reported as the average ± deviation standard of 4 different samples. 
2.3.8 3D In Vitro Biocompatibility and Osteogenic Differentiation Studies 
To encapsulate the hASCs into the nanocomposites, hASCs pellets were resuspended in 
each nanocomposite (0, 0.5, 1, and 2 mg/mL ND) prepolymer solution for a final concentration 
of 1 million cells/mL. Prepolymer solutions were then UV crosslinked at 7 mW/cm2 for 60 
seconds. Biocompatibility studies were carried out using an MTT assay and calcein-AM 
(Invitrogen, USA) staining at 72 hours, both according to the manufacturer’s protocol. 
For differentiation studies, hASCs (1 million cells/mL) were encapsulated as above 
within GelMA containing etiher 0 mg/mL ND, 1 mg/mL ND, 1 mg/mL ND and 1 µM Dex, or 
only 1 µM Dex. Cells were cultured in complete media for the first 48 hours after seeding, then 
osteoconductive media containing 50 µM ascorbic acid and 10 mM β-glycerophosphate for the 
remainder of the study. ALP activity at 14 days was quantified by p-nitrophenyl phosphate 
(pNPP) colorimetric assay (Sigma-Aldrich, USA) then normalized to DNA content. DNA 
content was determined using a PicoGreen kit (Invitrogen, USA). Briefly, nanocomposites were 
rinsed in PBS, lysed with lysis buffer, freeze-thawed once, sonicated, then centrifuged at 8,000 
rpm for 10 minutes. The DNA content of the supernatant was then quantified. For Alizarin Red S 
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staining, at 14 and 21 days, cells were fixed in 4% paraformaldehyde, washed with PBS three 
times, then incubated with 2% Alizarin Red S (Sigma) for 20 minutes. After washing with PBS 
three times to remove any excess stain, brightfield images of the nanocomposites were taken. 
Calcium in each nanocomposite group was quantified by first determining the wet weight of each 
gel then freezing and lyophilizing the samples. The nanocomposites were then allowed to vortex 
overnight in 0.5 M hydrochloric acid for homogenization. The resulting supernatants were 
analyzed for calcium content via a colorimetric assay (Sigma-Aldrich, USA) per the 
manufacturer’s protocol, then normalized to the wet weight of the hydrogel (µg/mg).  
2.3.9 Statistical Analysis 
Quantitative results are presented as mean ± standard deviation (SD) from independent 
experiments. Statistics were performed using a one-way ANOVA with a Tukey’s post hoc test. A 
p value of < 0.05 was considered significant. 
 
2.4 Results 
2.4.1 Dex Loading on NDs 
NDs have previously been shown to load poorly water soluble drugs, like Dex, through 
several theorized mechanisms [86]. To evaluate NDs’ potential to load Dex, we analyzed 
centrifuged complexes by FTIR and EDX analysis. FTIR spectroscopy confirmed the presence 
of carbonyl groups (1714 cm-1, ν C=O), hydroxyl groups (3421 cm-1, ν O-H) and alkyl groups 
(2917 cm-1, ν C-H) on the NDs (Figure 2.1). After centrifugation of a 10:1 ND:Dex (w/w) 
suspension, FTIR analysis of the resulting pellet showed characteristic peaks of Dex (1705 cm-1, 
ν C=O; 1658 cm-1 and 1618 cm-1, ν C=C) in the complex (Figure 2.1). TEM/EDX analysis 
showed a thoroughly dispersed suspension with NDs of ~5 nm diameter and confirmed the 
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presence of oxygen (Figure 2.2). TEM/EDX analysis of the ND-Dex pellet revealed fluorine in 
the complex, which was absent from the TEM/EDX of NDs (Figure 2.2). 
For hASC differentiation studies, proper dosing of Dex required a quantitative 
assessment of loading. Because of the broad UV absorbance of NDs which overlaps with the 
absorbance profile of Dex, we chose to use Dex-FITC for quantitative loading studies due to its 
characteristic absorbace peak outside of the UV range. UV-Vis spectroscopy analysis of 10:1 
ND:Dex-FITC pre- and post- spindown suspensions yielded a loading percentage of 65 ± 3% 
(Figure 2.3). However, it is important to note that FITC is a large addition to Dex that certainly 
contributes to loading in numerous ways. Because the surfaces of the NDs contain a mixture of 
functional groups, we theorize that a mix between hydrogen bonding, dipole-dipole interactions 
with surface oxygen groups, physisorption, and hydrophobic effects are responsible for the 
formation of the complex. 
2.4.2 ND-Dex Interactions with hASCs 
We next investigated the capability of the NDs to interact with the hASCs as well as 
deliver and release Dex. To confirm successful Dex delivery to the cells, we quantified several 
related genes. Serum/glucocorticoid regulated kinase 1 (SGK1) overexpression was recently 
identified as the first step in osteogenic differentiation of MSCs due to Dex exposure [87]. After 
incubation for one hour with a centrifuged then resuspended ND-Dex pellet, hASCs showed 
significantly higher expression of SGK1 compared to resuspended NDs and a negative control 
containing no NDs or Dex (Figure 2.4). MSCs are also known to produce more integrin α5 and 
β1 (ITGA5, ITGB1) as well as increase extracellular deposition of fibronectin for integrin α5β1 
anchoring [88]. Accordingly, ND-Dex exposure for six hours significantly increased ITGA5 
expression compared to controls (Figure 2.4). Increased focal adhesion stability leads to a higher 
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number of focal adhesions upon Dex exposure. Immunostain of paxillin (PXN), a protein which 
participates in focal adhesion activity by binding to β-integrin cytoplasmic domains, was 
observed to be more extensive in hASCs in response to both ND-Dex and Dex (Figure 2.5). 
2.4.3 Physical and Mechanical Characterization of GelMA/ND Nanocomposites 
GelMA/ND nanocomposites (NCs) at concentrations of 0.5, 1, and 2 mg/mL were 
fabricated and characterized. SEM images of both GelMA and 2 mg/mL GelMA-ND gels 
revealed similar interconnected porous networks in all groups. (Figure 2.7). The swelling ratio, 
crucial to determine the ability of hydrogels to exchange waste and nutrients with surrounding 
fluid, was measured in PBS at pH 7.4 at 37 °C. No significant differences were seen between 
GelMA and 2 mg/mL GelMA-ND at each swelling time point (Figure 2.7). Similar swelling 
ratios between the two systems corroborates the similar porosity seen in the SEM images. 
Elastic moduli steadily increased with addition of NDs to the GelMA network, with 2 
mg/mL nearly doubling the modulus of GelMA alone as well as being significantly higher than 
0.5 mg/mL nanocomposites (Figure 2.8). Given these results, we focused on GelMA and the 2 
mg/mL system for the remaining mechanical studies. Ultimate fracture strength (UCS) was 
reached at ~80% strain for GelMA and 2 mg/mL nanocomposites and the presence of the NDs 
again nearly doubled the UCS (~260 kPa vs. ~180 kPa) in representative samples (Figure 2.8). 
The rheology of the gels, as measured by an oscillatory frequency sweep, also changed 
significantly for the 2 mg/mL nanocomposites compared to the GelMA (Figure 2.8). Both the 
storage (G’) and loss (G’’) moduli were increased for all frequencies tested upon addition of 
NDs. The frequency sweeps in both cases showed G’ and G’’ curves consistent with highly 
crosslinked gels, in which G’ and G’’ both remained stable up until the final frequency, with 
very little variation throughout the test. 
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2.4.4 ND and GelMA-ND Biocompatibility Studies 
Extensive evaluation of nanomaterial biocompatibility is crucial for determining their 
suitability for drug delivery and cellular uptake. Thus, we proceeded with a more thorough 
investigation of ND biocompatibility with hASCs. qPCR analysis revealed no difference in the 
expression of a variety of pro- and anti-apoptotic genes when hASCs were exposed to NDs for 
12 hours (Figure 2.6). Likewise, concentrations of NDs ranging from 10-100 µg/mL showed no 
significant reduction in viability and proliferation in an MTT assay (Figure 2.6). 
We next tested the biocompatibility of the hASCs upon encapsulation within GelMA and 
the nanocomposites. Prepolymer solutions of GelMA and each ND concentration containing 1 
million cells/mL, were UV crosslinked for 60 seconds to form the constructs. hASCs showed 
excellent viability and spindle-like morphology after 72 hours. MTT assay confirmed no 
significant changes in viability between hASCs encapsulated in the three ND concentrations (0.5, 
1, and 2 mg/mL) as well as GelMA alone (Figure 2.9). Calcein-AM staining, again at 72 hours, 
showed cells adhering and stretching throughout the entire network of the GelMA and 
nanocomposites hydrogels (Figure 2.9). 
2.4.5 Micropatterning of GelMA-ND Nanocomposites 
Refining both 3D cell culture for drug discovery and mechanistic studies, as well as 
furthering regenerative medicine technologies, requires further control over the microstructure of 
constructs. GelMA has been previously used for this purpose and shows potential to create 
complex, ordered structures [74]. Cylindrical 1 mm micropatterns of both GelMA and 1 mg/mL 
nanocomposites were fabricated. Nanocomposites appeared to have more defined structure 
according to SEM and brightfield images. GelMA/ND nanocomposites containing 1 mg/mL NDs 
encapsulating 1 million hASCs/mL were successfully used to create cell-laden micropatterns. 
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Calcein-AM staining at 5 and 10 days showed excellent cell viability and spreading within the 
microgels (Figure 2.10). 
2.4.6 Osteogenic Differentiation of Encapsulated hASCs within GelMA/ND-Dex 
Release of Dex-FITC from nanocomposite hydrogels was significantly extended 
compared to GelMA controls. At 72 hours, ~50% of encapsulated Dex-FITC remained in the 
nanocomposites compared to less than 10% in GelMA hydrogels (Figure 2.11). These non-
Fickian release kinetics can be attributed to a variety of possible interactions, such as hydrogen 
bonding, physisorption, and hydrophobic effect. After proving the enhanced retention of Dex in 
the nanocomposite hydrogels, we investigated the potential of this system to initiate osteogenic 
differentiation of encapsulated hASCs. The nanocomposite hydrogels containing Dex showed 
superior osteogenic differentiation compared to all controls as measured by ALP activity and 
staining, calcium deposition, and osteocalcin staining. 
ALP activity, an early marker of osteogenic differentiation, increases intracellular 
concentrations of free phosphate by hydrolysis of pyrophosphate [89]. Both quantitative and 
qualitative evaluations of ALP activity were performed at 14 days. ALP activity (Figure 2.10) 
was increased significantly compared to all other groups in the ND-Dex group, and qualitative 
staining of ALP corroborated this finding (Figure 2.12). Alizarin Red S colorimetric stain allows 
qualitative comparison of bone-like calcium deposits. At both 14 and 21 days, all control groups 
showed minor mineralization, while ND-Dex showed significantly more red staining and thus 
calcium deposition (Figure 2.13). Finally, immunostaining for osteocalcin (OCN) provided 
further evidence for successful osteogenic differentiation of hASCs. OCN is an osteoblast-
specific marker that serves both endocrine functions and mineralization functions. ND-Dex 
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nanocomposites showed increased OCN staining, while control groups displayed very little or no 
staining (Figure 2.14).  
2.5 Discussion 
Dexamethasone loading on NDs was successful as confirmed by several methods, 
specifically at a ratio of 10:1 ND:Dex. Other studies have shown similar results when loading 
small molecules onto NDs [67, 86], though the exact mechanism of loading in this case requires 
further investigation. Analysis of our NDs showed a heterogeneous surface chemistry composed 
of a mixture of carbonyl, alcohol, and alkyl groups. As a result, it is not possible to speculate as 
to the exact mechanism of loading, be it through hydrogen bonding, dipole-dipole interactions 
between Dex and carbonyl groups, physisorption by van der Waal forces, or hydrophobic effects 
forcing interaction between the two. Previous studies of hydrophobic drugs and ND 
complexation were hypothesized to be primarily due to interactions with surface carboxyl groups 
[86]. The several hydroxyl groups available on Dex make hydrogen bonding with surface 
carbonyl groups in our case a possibility; in addition, hydrophobic regions of ND surfaces can 
interact with hydrophobic Dex through physisorption. Further studies to determine the loading 
mechanism should assess the loading efficiency of a panel of NDs with varying surface 
functionalizations. Our quantification of loading includes the effect of FITC and thus may not be 
completely accurate, given that FITC is comparable to Dex in molecular weight and also 
contains groups capable of interacting with the ND surface. 
The improvement of GelMA mechanical properties in response to ND addition was 
encouraging, given that other carbon nanomaterials have shown similar results both when simply 
added to the GelMA network [90, 91] and when covalently linked to it [92]. This revelation is 
particularly important in the context of UV crosslinkable gels, since NDs do absorb UV light and 
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certain types have even been explored as a UV protectant [93]. Interestingly, the mechanical 
properties showed a significant increase while no discernable changes in porosity or swelling 
ratio were observed upon ND addition to the network. Previous studies have shown both 
increases [55] and decreases [94], depending on the nanomaterial included, in porosity along 
with increased mechanical strength. For instance, enhanced ionic interactions between charged 
silica nanoparticles and amine and carboxyl groups contained in GelMA resulted in increased 
mechanical strength but also increased pore size [55]. The lack of physical change in our 
hydrogels suggests that GelMA crosslinking in this case has significantly more control over the 
swelling and porosity properties of the gel. 
NDs are well-known to be biocompatible as measured by higher cell viability at varying 
concentrations and lower reactive oxygen species production compared to graphene and CNTs; 
however, different carbon nanomaterials have been shown to have different cytotoxicities on 
varying cell type [95]. As expected, the NDs showed excellent biocompatibility, both by MTT 
assay and qPCR studies for a variety of anti- and pro-apoptotic markers. qPCR offered a more 
refined look at potential sources of apoptosis or anti-apoptosis. No significant differences 
between the negative control and ND exposed cells were observed, further confirming the 
biocompatibility of NDs with hASCs. Each chosen apoptotic gene has been shown to be related 
to mitochondrial regulated apoptosis, which carbon nanomaterials, particularly those inducing 
oxidative stress, have been shown to initiate [96-98]. Much current work focuses on lysosomal 
and autophagic disruption as mechanisms for nanomaterial-induced apoptosis [99]; though NDs 
have so far shown excellent biocompatibility, investigating these sources of apoptosis could 
further our understanding of why NDs have less toxicity than other carbon nanomaterials. 
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Studies on lysosomal disruption also have important implications for ND-based drug delivery, as 
NDs are mostly taken up by this route. 
Generally, NDs show much higher cellular uptake than other carbon nanomaterials [66] 
and appear to be taken up by clathrin-mediated endocytosis, with individual nanodiamonds 
localizing to the cytosol and larger complexes remaining in vesicles [100]. The cellular uptake, 
drug delivery capabilities, and biocompatibility of NDs by several cell types has been 
characterized, but this study is the first of our knowledge to report their capabilities with regards 
to stem cells. SGK1 overexpression in response to Dex increases microtubule instability, focal 
adhesion number and stability, and in turn intracellular tension and osteogenic gene expression 
[87]. Its overexpression, along with the noted cytoskeletal markers, confirmed that the ND-Dex 
complex was capable of delivering Dex in two possible ways: either Dex was released from ND-
Dex complexes and diffused into the cell, or NDs adsorbing Dex were taken up by the cell and 
Dex was released therein. For 3D in vitro and therapeutic applications, the second mechanism 
would be preferable; as cells spread and move within the nanocomposites, more NDs are taken 
up and exposed to adsorbed Dex, while Dex release to the surrounding fluid is limited. 
Understanding the kinetics of ND-Dex and other drug interactions along with which of these 
mechanisms dominates is a crucial subject for future research. Regardless of the exact 
mechanism of Dex delivery to the hASCs in this study, we were able to control release of Dex by  





Conclusion and Future Directions 
We successfully demonstrated NDs’ capabilities to load and deliver Dex, synthesized and 
characterized GelMA/ND nanocomposites, furthered study of the biocompatibility of NDs with 
mesenchymal stem cells, and finally succeeded in 3D osteogenic differentiation using the 
loading ability of our NDs in conjunction with GelMA. Successful loading and delivery of Dex, 
along with the improvement in mechanical properties of GelMA by NDs, demonstrates their 
potential for tissue engineering applications, encourages future studies, and also provides another 
example of their well-established drug delivery capabilities. However, further characterization of 
the NDs and Dex from this study must be performed to fully understand complexation and its 
influence on drug loading and release from the NDs. In order to evaluate the influence of Dex on 
the aggregation of NDs as well as the colloidal stability of ND-Dex complexes compared to NDs 
alone, we plan on performing dynamic light scattering (DLS) as well as zeta potential analysis to 
observe ND-Dex aggregate size and stability. In addition, though our release study did 
demonstrate that NDs were able to extend Dex retention within GelMA, further work can be 
done to postulate how this occurred. The release observed from GelMA alone appeared to be 
standard Fickian release, while the GelMA-ND study appeared to show a short burst release, 
followed by a more extended retention of Dex by the NDs. It is possible that Dex that was 
uncomplexed with NDs was released in short order, while complexed Dex was required to 
desorb from the ND surface, then release into the surrounding media. We will seek to fit 
different models to this release profile, which may lend insight into what the dominant 
mechanism of release is. 
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Given the success of this design, future work can be done to evaluate its in vivo 
effectiveness in a cranial defect model. An in vivo study will require additional work to be able 
to effectively deliver the hydrogel to a variety of defects of different size and shape, given that 
GelMA is not realistically an injectable material. We are currently evaluating the capability to 
3D bioprint GelMA-ND prepolymer solutions containing hASCs.  This study could also be an 
excellent opportunity to evaluate the potential of NDs for clinical translation from a broader 
perspective, with a focus on their biodistribution and potential toxicity after degradation of a 
hydrogel-ND scaffold. A study in parallel that uses fluorescent NDs, ideally with a similar 
surface chemistry, integrated into a GelMA network could enable study of biodistribution after 
different degradation time points. Observing the functionality and health of tissues with high ND 
load after implantation is crucial to tuning future clinical applications of NDs. Biodistribution 
studies must also include an assessment of how and if the NDs are cleared. In our application, 
quick clearance of both NDs that elute out of the One potential avenue of study is observation of 
protein adsorption, significant amounts of which can lead to quick excretion by the liver. We are 
interested in pairing this concept with our study on GelMA-ND degradation in vitro, in addition 
to studying it in vivo eventually.  
As expected based on previous work with other carbon nanomaterials, NDs were able to 
improve the mechanical properties of GelMA through the nanofilling effect. Theoretically, NDs 
participate in the GelMA network via transient interactions, allowing them to bear some load 
upon disturbance of the network. However, given that the NDs do have sites available for free 
radical formation upon contact with a photoinitiator, it is possible that some NDs are able to 
crosslink covalently with the polymer itself. How frequently this occurs and its influence on 
GelMA mechanical properties is another opportunity for future study. Though NDs did improve 
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the strength of the GelMA network, the improvement was certainly not enough for the hydrogel 
to be used alone in a load-bearing application. However, discarding hydrogels such as this one 
for use in load-bearing defects would be unwise given their versatility and ability to mimic 
endochondral ossification. Thus, we are interested in the possibility of creating biphasic scaffolds 
by integrating this and other osteoinductive hydrogels with stronger synthetic scaffolding 
materials for the treatment of load-bearing defects. In particular, 3D-printed scaffolds with 
moderate porosity for filling with osteoinductive hydrogels might provide the mechanical 
strength necessary for these defects, while also having surface area available for hydrogel 
coating and crosslinking.  
Success in this study can be expanded upon in a number of ways. Perhaps the most 
glaring deficiency of this study is that we took little advantage of one of the greatest assets of 
NDs: their tailorable surface chemistry. As previously mentioned, studies on NDs have produced 
many surface-functionalizations which can be utilized in tissue engineering. One concept that 
has been pursued with other nanomaterials, including graphene and CNTs, is covalent 
immobilization onto the scaffolding hydrogel. Higher increases to stiffness have been observed 
with this method compared to the simple filling used in this study, especially at higher 
nanomaterial concentration. A minor increase in compressive strength was achieved in this 
project, but we theorize a significantly larger one could be gained by this method, as the NDs are 
no longer a simple filling agent but are chemically integrated into the network. Similarly, drugs 
have been covalently linked to NDs to further control over release. An exciting approach would 
be to combine these capabilities; simultaneous linking of drug and polymer to NDs could lead to 
more robust hydrogels with enhanced release profiles depending on the application. We are 
currently exploring the possibility of a one-step reaction to link both Dex and GelMA to 
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functionalized NDs. Clearly, this strategy would apply beyond bone tissue engineering. For 
example, acid-sensitive linkages to both polymer and drug are an intriguing possibility for cancer 
therapy; NDs’ demonstrated ability to localize to tumors and avoid drug efflux, coupled with 
controlled degradation and release in the tumor microenvironment may lead to an effective 
therapy. 
Imaging with fluorescent NDs also hold intriguing possibilities in tissue engineering and 
bone tissue engineering. As mentioned in previous sections, an octadecylamine-functionalized 
NDs coating on PLLA implants allowed imaging of implants. In vitro, fluorescent microscale 
beads are frequently used for studies of cell migration and tracking. Filling hydrogels with 
fluorescent NDs could allow studies of cellular migration and traction in a 3D matrix, much in 
the same way these larger fluorescent beads can. If the distribution of fluorescent NDs could be 
controlled, they might allow finer tracking of cells. Where fluorescent NDs may be especially 
useful is in the imaging and tracking of implanted gels or implants in vivo; perhaps real time 
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Summary of Bone Tissue Engineering Strategies. Numerous scaffolds, therapeutics, and 
mechanical stimulation strategies have been explored for regenerating bone tissue. Ideal 
scaffolds must have controlled porosity and degradation profiles, encourage vascularization of 
newly forming bone tissue, and enable the controlled, local delivery of cells and drugs. 
(Reprinted from Advanced Drug Delivery Reviews, Biomimetic approaches in bone tissue 
engineering: Integrating biological and physicomechanical strategies, 84: 1-29, Fernandez-Yague 





Nanodiamond-based Drug Delivery. Nanodiamonds, with some modification, are capable of 
delivering a wide variety of therapeutic types. Small molecules and proteins adsorb to the surface 
of carboxylated NDs in many cases, while delivery of nucleic acids can be achieved by first 
complexing NDs with positively charged polymers, such as polyethylenimine. (Reproduced from 








FTIR Spectra of ND-Dex and Proposed Interactions. (A) Characteristic peaks of both NDs 
and Dex are visible in the complex. (B) Schematic representing the possible interactions between 





















TEM/EDX Analysis. (A) TEM/EDX analysis of ND suspension. TEM images showing well-
dispersed NDs suspension in water (Scale bar = 20 nm). EDX analysis showed the presence of 
carbon and oxygen on the NDs surface. (B) TEM/EDX analysis of ND-Dex complex revealed 


















UV-Visible spectra of NDs and ND-Dex-FITC complex pre- and post- centrifugation (A) 
Picture showing the suspension of NDs and Dex-FITC prior to centrifugation. Complex was 
formed by mixing Dex-FITC and NDs at a ratio of 1:10. UV-Vis spectra of the ND suspension, 
Dex-FITC and the complex in the range of 400-600 nm.  (B) UV-Vis spectra showing the 
disappearance of the peak relative to the ND-Dex FITC complex compared to the solution of 

















qPCR analysis of Dex-induced genes in hASCs. (A) Relative expression of SGK-1, following 
one hour of exposure to hASCs. Both Dex and the ND-Dex complex respectively showed a 
significant increase in SGK-1 expression. (B) Relative expression of cytoskeletal element 
integrin α5 (ITGA5) following six hours of exposure to hASCs. ND-Dex and Dex both 




Focal Adhesion Staining After Dex Exposure. Fluorescence immunostaining of paxillin for 
hASCs showing an increase in the number of focal adhesion after 24 hours of Dex exposure. The 













Biocompatibility Analysis of NDs in 2D. (A) MTT Assay of hASCs exposed to varying 
concentrations of NDs. Up until 200 µg/mL, NDs showed no significant toxicity. (B) qPCR 
analysis of a variety of apoptotic markers. hASCs exposed to 25 µg/mL showed no significant 


















Nanocomposite hydrogel physical characterization. (A) Images of nanocomposite hydrogels 
with increasing concentration of NDs. (Scale bar = 15 mm). (B) SEM images of GelMA scaffold 
with and without NDs showing similar porosity. (Scale bar = 100 µm). (C) Swelling ratio of 
nanocomposite hydrogels over time showing a steady increase in the values for both groups (* = 


























Mechanical and rheological studies of ND-GelMA nanocomposites hydrogels. (A) Young’s 
modulus of different nanocomposite hydrogels with varying concentration of NDs. A significant 
increase was observed for the group containing 2 mg/mL of NDs. (* = p <0.05, n=4). (B) Stress 
strain curves obtained after uniaxial compression showing an increase in the ultimate fracture 
strength for the group containing NDs at the concentration of 2 mg/mL.  (C) Frequency sweeps 
carried out in the range of 0.01 up to 10 Hz showed an increase in the value of the storage 
modulus (G’) for the system containing NDs. The increase could be attributed to noncovalent 























Nanocomposite Biocompatibility and 3D hASC Encapsulation. (A) MTT study of hASCs 
encapsulated in the nanocomposite GelMA hydrogels showed excellent biocompatibility 
regardless of the ND concentration (0-2 mg/mL). (B) Calcein-AM staining indicated hASCs 
spindle-like morphology and stretching throughout the network for both groups (ND 









Nanocomposite Micropatterning and 3D hASC Encapsulation (A) Brightfield images (top) 
and SEM images (bottom) of 1 mm cylindrical GelMA and GelMA-ND micropatterns. 
(Brightfield scale bar = 1 mm, SEM scale bar = 500 μm) (B) Calcein-AM staining of hASCs at 5 
and 10 days showed that cells were viable within the micropatterned nanocomposites. (Scale bar 






























Dex-FITC Release from Nanocomposites. Nanocomposite hydrogels significantly extended the 
release of Dex-FITC. At three days, only half of Dex-FITC had eluted out of the 


























ALP Differentiation Studies. (A) ALP quantification of hASCs after 14 days of culture in 
osteoconductive media showing a significant increase in ALP expression for the nanocomposite 
system compared to control groups. (*** = p <0.001, n=3). (B) ALP staining of hASCs 
encapsulated in GelMA hydrogels indicating a higher expression of ALP in the group containing 























Alizarin Red Staining and Quantification. (A) Calcium quantification after 14 and 21 days of 
hASC differentiation using osteoconductive media. At both times points a higher amount of 
calcium was detected for the ND-Dex group compared to the other groups tested (*** = p < 
0.001 n =3). (B) Calcium was quantified by colorimetric assay and observed using Alizarin Red 
S staining at 14 days and 21 days. This staining qualitatively confirmed the higher amount of 





























Osteocalcin Staining. Encapsulated hASCs were stained for osteocalcin, a gene associated with 
hydroxyapatite binding and solely secreted by osteoblasts, after 21 days. Significantly more 
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